NKG2D
Showing 1 - 25 of >10,000
Advanced Sarcoma Trial (NKG2D-CAR memory T cell)
Not yet recruiting
- Advanced Sarcoma
- NKG2D-CAR memory T cell
- (no location specified)
Oct 17, 2023
Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)
Recruiting
- Ovarian Cancer
- NKG2D CAR-NK
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Mar 26, 2023
AML Trial in Hangzhou (NKG2D CAR-NK)
Recruiting
- AML
- NKG2D CAR-NK
-
Hangzhou, Zhejiang, China
- +1 more
Feb 17, 2023
Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)
Not yet recruiting
- Gastric Cancer
- +2 more
- KD-496
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Nov 15, 2023
Refractory Metastatic Colorectal Cancer Trial in Hangzhou (NKG2D CAR-NK)
Recruiting
- Refractory Metastatic Colorectal Cancer
- NKG2D CAR-NK
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University
Jan 16, 2022
Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)
Recruiting
- Gastric Cancer
- +2 more
- KD-496
-
Beijing, ChinaChinese PLA General Hospital
Oct 13, 2022
Refractory Metastatic Colorectal Cancer Trial in Guangzhou (CAR-T infusion)
Recruiting
- Refractory Metastatic Colorectal Cancer
- CAR-T infusion
-
Guangzhou, Guangdong, ChinaThe Third Affiliated Hospital of Guangzhou Medical University
Feb 9, 2022
Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)
Recruiting
- Hepatocellular Carcinoma
- +3 more
- NKG2D-based CAR T-cells
-
Jiujiang, Jiangxi, ChinaXunyang Changchun Shihua Hospital
Nov 20, 2021
Safety and Efficacy Trial in Sanhe (CAR-NK cells)
Recruiting
- Safety and Efficacy
- CAR-NK cells
-
Sanhe, Hebei, ChinaHebei Yanda Lu Daopei Hospital
Feb 9, 2022
CRC, Solid Tumor Trial in Beijing (KD-025)
Recruiting
- CRC
- Solid Tumor
- KD-025
-
Beijing, Beijing, ChinaChinese PLA General Hospital
May 16, 2022
Advanced Solid Tumors Trial in Hangzhou (Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))
Recruiting
- Advanced Solid Tumors
- Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
-
Hangzhou, ChinaFirst affiliated hospital, School of Medicine, Zhejiang Universi
Aug 3, 2023
Advanced Solid Tumor Trial in Shanghai (IMC008)
Recruiting
- Advanced Solid Tumor
-
Shanghai, Shanghai, ChinaShanghai Changhai Hospital
Apr 19, 2023
Acute Myeloid Leukemia Trial (NK cells, Talazoparib 1 MG [Talzenna])
Not yet recruiting
- Acute Myeloid Leukemia
- NK cells
- Talazoparib 1 MG [Talzenna]
- (no location specified)
Jan 9, 2023
Cancer, Malignancy, Refractory Cancer Trial in Singapore (Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted ?d T
Not yet recruiting
- Cancer
- +3 more
- Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
-
Singapore, SingaporeNational University Hospital
Mar 20, 2022
Recurrent Glioblastoma Trial (NKG2D CAR-T)
Not yet recruiting
- Recurrent Glioblastoma
- NKG2D CAR-T
- (no location specified)
Jan 16, 2021
Acute Myeloid Leukemia Trial in Hangzhou (NKG2D CAR T-cells)
Not yet recruiting
- Acute Myeloid Leukemia
- NKG2D CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
Dec 5, 2020
Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)
Withdrawn
- Hepatocellular Carcinoma
- +3 more
- NKG2D-based CAR T-cells
-
Jiujiang, Jiangxi, ChinaAffiliated hospital of jiujiang university
Oct 18, 2020
COVID-19 Trial in Chongqing (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)
Recruiting
- COVID-19
- NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
-
Chongqing, ChinaChongqing Public Health Medical Center
Nov 16, 2020
Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer Trial in Nanjing (KD-025 CAR-T cells)
Not yet recruiting
- Solid Tumor
- +3 more
- KD-025 CAR-T cells
-
Nanjing, Jiangsu, ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University
Sep 20, 2020
Unresectable Metastatic Colorectal Cancer Trial in Belgium, United States (CYAD-101, FOLFOX, FOLFIRI)
Recruiting
- Unresectable Metastatic Colorectal Cancer
- CYAD-101
- +2 more
-
Tampa, Florida
- +3 more
Nov 19, 2020
Colon Cancer Liver Metastasis Trial in Brussels (NKR-2 cells)
Unknown status
- Colon Cancer Liver Metastasis
- NKR-2 cells
-
Brussels, BelgiumInstitut Jules Bordet
Jun 18, 2020
Colon Cancer Liver Metastasis Trial in Brussels, Charleroi, Leuven (NKR-2 cells)
Unknown status
- Colon Cancer Liver Metastasis
- NKR-2 cells
-
Brussels, Belgium
- +3 more
Jun 15, 2020
MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)
Not yet recruiting
- MSI-H/dMMR Gastroesophageal-junction Cancer
- MSI-H/dMMR Gastric Cancer
- S095029
- Pembrolizumab 200 mg
- (no location specified)
Oct 30, 2023
SARS-CoV-2 (COVID-19) Infection, Advanced or Metastatic Hematological or Solid Tumor Trial in France (Autophagy inhibitor
Completed
- SARS-CoV-2 (COVID-19) Infection
- Advanced or Metastatic Hematological or Solid Tumor
- Autophagy inhibitor (GNS651)
- +3 more
-
Lyon, Rhône, France
- +11 more
Sep 29, 2022
Relapsed/Refractory AML, AML, Adult, MDS Trial in United States (NKX101 - CAR NK cell therapy)
Recruiting
- Relapsed/Refractory AML
- +3 more
- NKX101 - CAR NK cell therapy
-
Denver, Colorado
- +6 more
Apr 8, 2022